Cargando…
Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial
Background Apremilast is an oral phosphodiesterase-4 enzyme inhibitor that modulates the immune system by increasing intracellular cyclic adenosine monophosphate levels and inhibiting inflammatory cytokines synthesis. We aimed to compare the efficacy and safety of add-on apremilast in combination th...
Autores principales: | Sharma, Sakshi, Bhardwaj, Abhishek, Dwivedi, Pradeep, Yadav, Suraj Singh, Shamim, Muhammad Aaqib, Singh, Surjit, Sharma, Prem Prakash, Ambwani, Sneha, SIngh, Kuldeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162885/ https://www.ncbi.nlm.nih.gov/pubmed/37153322 http://dx.doi.org/10.7759/cureus.37180 |
Ejemplares similares
-
Apremilast in the Management of Disseminated Granuloma Annulare
por: Joshi, Tejas P, et al.
Publicado: (2021) -
Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023) -
Repigmentation of Tenacious Vitiligo on Apremilast
por: Huff, Sara B., et al.
Publicado: (2017) -
Vitiligo-Associated Autoimmune Disorders: A Woman With Vitiligo and Incipient Hypothyroidism
por: Malik, Sara, et al.
Publicado: (2021) -
The Safety and Effectiveness of Decapeptide in Patients With Vitiligo: A Real-World Study
por: Sharma, Aseem, et al.
Publicado: (2023)